Argenx SE

Argenx SE’s May 2026 AGM will review 2025 results and board changes, spotlighting its high‑margin specialty portfolio, digital therapy plans, and payer‑focused strategies.

Argenx SE’s 2026 AGM reveals board changes, a $25‑$30k FcRn blocker strategy, 10‑year patent window, and M&A plans to sustain growth beyond 2034 patent cliffs.

Argenx’s regulatory setbacks in Europe could slash projected revenue by 41% and erode NPV. Discover how data‑package expansion, outcome‑based pricing, and targeted M&A may salvage growth.

Argenx’s Efgarti faces regulatory delays that could push market launch 18‑24 months, but its performance‑linked pricing and RWE strategy aim to secure EU reimbursement and lift future profits.

Argenx SE to reveal new clinical data on efgartigimod for myasthenia gravis and CIDP at the 2026 AAN meeting—showcasing its antibody‑blockade platform’s potential to reshape the $3.2 bn autoimmune neurology market and impact investor outlook.

Argenx SE investor update: upcoming Q4 earnings reveal pipeline progress, regulatory milestones, and commercial strategy for autoimmune and oncology antibody therapies.

Argenx SE unveils 2025 full‑year results and Q4 update: see revenue trends, pipeline progress, and market positioning in its Feb. 26 webcast.

Argenx shares swing after FDA grants priority review for Vyvgart’s new myasthenia gravis indication, boosting outlook and revealing the company’s strategy to diversify beyond oncology.

Argenx’s VYVGART gains FDA priority‑review for seronegative generalized myasthenia gravis, offering early, evidence‑based hope for a rare, underserved patient group.

Argenx SE’s biotech stock climbs on a premium valuation driven by its antibody platform, breakthrough CD73 oncology trials, and strong autoimmune data—an attractive blend of scientific promise and market confidence for investors.